Showing 4871-4880 of 5623 results for "".
- Tearlab Acquired by Accelmed Partners for $25 Millionhttps://modernod.com/news/tearlab-acquired-by-accelmed-partners-for-25-million/2477742/Private equity firm Accelmed Partners II (AP-II) has agreed to acquire TearLab for $25 million. The payment, which will be made over two tranches, will result in TearLab delisting from the “over the counter” OTCQB mar
- jCyte Enters Into Ex-US Licensing and Commercialization Agreement for jCell Therapy With Santenhttps://modernod.com/news/jcyte-enters-into-ex-us-licensing-and-commercialization-agreement-for-jcell-therapy-with-santen/2477727/jCyte Inc. announced it has entered into a licensing agreement with Santen Pharmaceutical to develop and commercialize its first-in-class, investigational therapy, jCell, outside the United States, in regions including Europe, Asia, and Japan. Under the terms of the licensing agreement, jC
- Hydroxychloroquine Fails to Help Hospitalized Coronavirus Patients in US Funded Studyhttps://modernod.com/news/hydroxychloroquine-fails-to-help-hospitalized-coronavirus-patients-in-us-funded-study/2477728/Hydroxychloroquine, a decades-old malaria drug, didn’t appear to help hospitalized patients with COVID-19, according to a new observational study published Thursday in the New England Journal of Medicine, according to a CN
- Insight Into FDA’s Revised Policy on Antibody Tests: Prioritizing Access and Accuracyhttps://modernod.com/news/insight-into-fdas-revised-policy-on-antibody-tests-prioritizing-access-and-accuracy/2477725/In a blog post on the FDA website, agency leaders outlined a new policy that aims to provide more oversight of COVID-19 antibody tests. The revised policy on antibody tests was written by Anand Shah, MD, Deputy Commissioner for Medical and Scientific Affairs, and Jeff Shuren, MD, Director,
- Sight Sciences Introduces the Next-Generation Omni Surgical System for Microinvasive Glaucoma Surgeryhttps://modernod.com/news/sight-sciences-introduces-the-next-generation-omni-surgical-system-for-microinvasive-glaucoma-surgery/2477720/Sight Sciences announced the launch of its next-generation Omni Surgical System for microinvasive glaucoma surgery (MIGS) procedures. The Omni Surgical System combines two distinct angle procedures—ab interno trabeculotomy and transluminal viscoelastic delivery. It is the only MIGS
- Bausch + Lomb Licenses Exclusive Rights To a Biosimilar Candidate for Lucentis (Ranibizumab) in the US and Canadahttps://modernod.com/news/bausch-lomb-licenses-exclusive-rights-to-a-biosimilar-candidate-for-lucentis-ranibizumab-in-the-us-and-canada/2477718/Bausch + Lomb has entered into an exclusive licensing agreement with STADA Arzneimittel AG and its development partner, Xbrane Biopharma AB, a Nordic biosimilar developer, to develop and commercialize a biosimilar candidate to Lucentis (ranibizumab) in the United States and Canada. The companies
- Lineage Cell Therapeutics Reports New Data With OpRegen for the Treatment of Dry AMD With Geographic Atrophyhttps://modernod.com/news/lineage-cell-therapeutics-reports-new-data-with-opregen-for-the-treatment-of-dry-amd-with-geographic-atrophy/2477713/Lineage Cell Therapeutics announced that updated results from a phase 1/2a study of its lead product candidate OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD), were published online via th
- World Leaders Pledge $8 Billion To Fight COVID-19; US Skips Meetinghttps://modernod.com/news/world-leaders-pledge-8-billion-to-fight-covid-19-us-skips-meeting/2477711/A global alliance responded to calls to fight the coronavirus pandemic on Monday, as world leaders pledged some $8 billion to develop vaccines and treatments to fight COVID-19, according to an NPR
- Massachusetts Eye and Ear Advancing Experimental Gene-Based COVID-19 Vaccine, AAVCOVIDhttps://modernod.com/news/massachusetts-eye-and-ear-advancing-experimental-gene-based-covid-19-vaccine-aavcovid/2477708/Massachusetts Eye and Ear and Massachusetts General Hospital (MGH), members of Mass General Brigham, announced progress toward the testing and development of an experimental vaccine called AAVCOVID, a novel gene-based vaccine candidate against SARS-CoV2, the virus that causes COVID-19. The
- Adverum Biotechnologies Reports Positive Interim Data of ADVM-022 Intravitreal Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-biotechnologies-reports-positive-interim-data-of-advm-022-intravitreal-gene-therapy-for-wet-amd/2477705/Adverum Biotechnologies announced new interim clinical data from Cohorts 1-3 of the OPTIC phase 1 dose-ranging clinical trial of ADVM-022 intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD) and provided